Author: Editor

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GU 2022 Abstract – Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GU 2022 Abstract – Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.  

Professor Amit Singal, Professor, Medical Director of the Liver Tumor Program, and Clinical Chief of Hepatology at University of Texas Southwestern Medical Center. In this video, he speaks about the ESMO Deep Dive 2022 – Primary and Secondary Prevention of Hepatocellular Carcinoma.    Hepatocellular Carcinoma -  This is the most frequent type of liver cancer. Hepatocellular carcinoma is most common in persons with liver disease, particularly chronic hepatitis B and C. Symptoms do not always develop in the early stages of cancer. Later symptoms include weight loss, upper abdominal pain, and skin discoloration (jaundice). Surgery, transplant, freezing or heating the…

Professor Amit Singal, Professor, Medical Director of the Liver Tumor Program, and Clinical Chief of Hepatology at University of Texas Southwestern Medical Center. In this video, he speaks about the ESMO Deep Dive 2022 – Primary and Secondary Prevention of Hepatocellular Carcinoma.  Hepatocellular Carcinoma -  This is the most frequent type of liver cancer. Hepatocellular carcinoma is most common in persons with liver disease, particularly chronic hepatitis B and C. Symptoms do not always develop in the early stages of cancer. Later symptoms include weight loss, upper abdominal pain, and skin discoloration (jaundice). Surgery, transplant, freezing or heating the cancer…

Shilpa Gupta, MD, Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. In this video, she speaks about the ASCO GU 2022 Abstract – Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study. Origins: The therapy options for la/mUC are changing. There is a scarcity of data on current la/mUC therapy patterns. Using qualitative interviews, this study examined physician treatment decision-making and prescribing trends in the United States (QIs). Methodologies: First, published abstracts from January 2018 to March 2021 were…

Shilpa Gupta, MD, Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. In this video, she speaks about the ASCO GU 2022 Abstract – Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study. Origins: The therapy options for la/mUC are changing. There is a scarcity of data on current la/mUC therapy patterns. Using qualitative interviews, this study examined physician treatment decision-making and prescribing trends in the United States (QIs). Methodologies: First, published abstracts from January 2018 to March 2021 were…

Guru Sonpavde, MD, Director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School at Harvard University. In this video, he speaks about the ASCO GU 2022 Abstract – Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) predicts outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).   Origins: ICIs have made strides in the treatment of mUC. However, determining the objective effectiveness of ICIs via radiographic imaging might take months and can be muddled by pseudoprogression. Immune cells infiltrating the tumor microenvironment appear to be reflected in peripheral blood…

Guru Sonpavde, MD, Director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School at Harvard University. In this video, he speaks about the ASCO GU 2022 Abstract – Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) predicts outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).     Origins:   ICIs have made strides in the treatment of mUC. However, determining the objective effectiveness of ICIs via radiographic imaging might take months and can be muddled by pseudoprogression. Immune cells infiltrating the tumor microenvironment appear to be reflected in…

Mya Roberson, Ph.D., Assistant Professor Health Policy at Vanderbilt University Medical School. In this video, she speaks about the article Let’s get critical: bringing Critical Race Theory into cancer research.   Critical Race Theory (CRT) was first defined in American academic legal study to describe the social creation of racial categories as a tool of oppression, as well as the systemic existence of racism in society. CRT is a term that refers to the societal power that allows one dominant socially constructed racial group to marginalize others, and it is not exclusive to the United States. Scholars in the health…

Mya Roberson, Ph.D., Assistant Professor Health Policy at Vanderbilt University Medical School. In this video, she speaks about the article Let’s get critical: bringing Critical Race Theory into cancer research.   Critical Race Theory (CRT) was first defined in American academic legal study to describe the social creation of racial categories as a tool of oppression, as well as the systemic existence of racism in society. CRT is a term that refers to the societal power that allows one dominant socially constructed racial group to marginalize others, and it is not exclusive to the United States. Scholars in the health…

Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center. In this video, he speaks about the ASCO GU 2022 Abstract – PROpel Phase III trial of Lynparza (olaparib) in combination with standard-of-care abiraterone.   Explanation in detail: PROpel is a phase III trial comparing the efficacy, safety, and tolerability of olaparib with placebo when given in combination with abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not previously received chemotherapy or novel hormonal agents (NHAs) (first-line setting). In PROpel, about 720 patients were to…

Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center. In this video, he speaks about the ASCO GU 2022 Abstract – PROpel Phase III trial of Lynparza (olaparib) in combination with standard-of-care abiraterone.   Explanation in detail: PROpel is a phase III trial comparing the efficacy, safety, and tolerability of olaparib with placebo when given in combination with abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not previously received chemotherapy or novel hormonal agents (NHAs) (first-line setting). In PROpel, about 720 patients were to…

Alicia K. Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program Dana-Farber Cancer Institute. In this video, she speaks about the ASCO GU 2022 Abstract – 16: (Rapid Abstract Session A) Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.     Origins:   A survey of PCa patients was done to map their experiences, expectations, and attitudes, as well as to identify obstacles and unmet needs in diagnosis, therapy patterns, care teams, QoL, patient groups, and resources. We provide the preliminary survey findings and…

Alicia K. Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program Dana-Farber Cancer Institute. In this video, she speaks about the ASCO GU 2022 Abstract – 16: (Rapid Abstract Session A) Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.     Origins:   A survey of PCa patients was done to map their experiences, expectations, and attitudes, as well as to identify obstacles and unmet needs in diagnosis, therapy patterns, care teams, QoL, patient groups, and resources. We provide the preliminary survey findings and…

Chris Schaber is Focused on Rare and Orphan Diseases with High Unmet Medical Need We recently spoke to Dr. Chris Schaber, President & CEO, Soligenix, Inc. on OncologyTube.  Soligenix (Nasdaq: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Dr. Schaber is extremely optimistic about the future of medicine and the progress he and his team are making with the Soligenix drug pipeline – especially their lead product called HyBryteâ„¢ for a devastating blood and skin cancer. HyBryteâ„¢ (SGX301 or synthetic hypericin) is a unique drug…

Bailey Gleason Fitzgerald, MD, Fellow, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai. In this video, she speaks about the IASLC 2022 Abstract Rapid Progression of Metastatic NSCLC treated with First Line Osimertinib: An Institutional Case Series.   Origins:   For patients with EGFR exon 19 or 21 mutant non-small cell lung cancer in the United States, osimertinib is the conventional first-line (1L) tyrosine kinase inhibitor (TKI) (NSCLC). The median PFS in the FLAURA study of 1L osimertinib was 18.9 months. However, the ORR was only 80%, indicating that 1L osimertinib may not be beneficial to a…

Bailey Gleason Fitzgerald, MD, Fellow, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai. In this video, she speaks about the IASLC 2022 Abstract Rapid Progression of Metastatic NSCLC treated with First Line Osimertinib: An Institutional Case Series.   Origins:   For patients with EGFR exon 19 or 21 mutant non-small cell lung cancer in the United States, osimertinib is the conventional first-line (1L) tyrosine kinase inhibitor (TKI) (NSCLC). The median PFS in the FLAURA study of 1L osimertinib was 18.9 months. However, the ORR was only 80%, indicating that 1L osimertinib may not be beneficial to a…

Miguel Garcia, MD, Clinical Research Fellow, Division of Medical Oncology & Hematology at University Health Network. In this video, he speaks about the IASLC 2022 Abstract – Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy.   Origins:   In advanced non-small cell lung cancer, molecular profiling of tumor tissue is the gold standard for therapeutic decision-making. However, due to a lack of biopsy samples, results are frequently delayed or unavailable. By finding circulating tumor DNA (ctDNA) in plasma, liquid biopsies can help with genotyping. As part of the pre-diagnostic work-up for lung cancer, we tested the use of…

Miguel Garcia, MD, Clinical Research Fellow, Division of Medical Oncology & Hematology at University Health Network. In this video, he speaks about the IASLC 2022 Abstract – Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy.   Origins:   In advanced non-small cell lung cancer, molecular profiling of tumor tissue is the gold standard for therapeutic decision-making. However, due to a lack of biopsy samples, results are frequently delayed or unavailable. By finding circulating tumor DNA (ctDNA) in plasma, liquid biopsies can help with genotyping. As part of the pre-diagnostic work-up for lung cancer, we tested the use of…

Kevin R. Krull, Ph.D., Member, St. Jude Faculty, Endowed Chair in Cancer Survivorship at St. Jude Children’s Research Hospital. In this video, he speaks about the article in ASH Clinical News – Long-Term Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Neurocognitive Impairment.     Neurocognitive impairment is more common in long-term survivors of juvenile Hodgkin lymphoma (HL). According to a study published in Blood, exercise and smoking are modifiable risk factors for this impairment that could be used as therapy targets to improve functional results.   A total of 1,781 adult HL survivors were enrolled in the multi-institutional Childhood…

Survivors of childhood Hodgkin’s Lymphoma have been an unrecognized group for a number of years because they don’t receive direct neurotoxic therapies. So, children’s oncology groups in North America define neurotoxic exposures as cranial radiation, high dose intrathecal, or methotrexate; high dose, intravenous methotrexate, or cytarabine and neurosurgery and Hodgkin’s Lymphoma survivors don’t receive any of them. They’ve been unrecognized as a risk group for a number of years. However, we see that they struggle when they hit adulthood. And we’ve been looking at their cognitive function in a number of ways. We see that they do develop problems with…

Jeroen Roose, Ph.D., Principal Investigator, and Hugo Gonzalez Velozo, Ph.D., Postdoctoral Fellow at UC San Francisco. This video talks about their study “Cellular architecture of human brain metastases,” which is a single-cell analysis of huma BrM that reveals multiple conserved features across multiple cancer and points the way to potential future improvements in immune therapies. With thanks to Joanna Phillips, MD, Ph.D., and Matthew Spitzer, Ph.D., who collaborated with Dr. Gonzalez Velozo. All this could not be possible without the late Zena Werb, Ph.D., for starting this with her visions for the future treatment.   “What we haven’t looked at…

Jeroen Roose, Ph.D., Principal Investigator, and Hugo Gonzalez Velozo, Ph.D., Postdoctoral Fellow at UC San Francisco. This video talks about their study “Cellular architecture of human brain metastases, ” which is a single-cell analysis of huma BrM that reveals multiple conserved features across multiple cancer and points the way to potential future improvements in immune therapies. With thanks to Joanna Phillips, MD, Ph.D., and Matthew Spitzer, Ph.D., who collaborated with Dr. Gonzalez Velozo. All this could not be possible without the late Zena Werb, Ph.D., for starting this with her visions for the future treatment.   “What we haven’t looked…

Rebecca Harrison, MD, Assistant Professor of Neuro-Oncology at MD Anderson and is now a Clinical Associate Professor BC Cancer the University of British Columbia. In this video, she speaks about the Neurologic Toxicities of Immunotherapy.   Overview:   Over the last two decades, immunotherapy has changed cancer treatment. Immunotherapy techniques’ anticancer results come at the cost of an increasing range of immune-related adverse events (irAEs) caused by cross-reactivity between tumor and normal host tissue. These negative events can occur in any organ and range in severity from moderate to severe, even life-threatening. While neurological irAEs linked with immune checkpoint inhibitors…

Rebecca Harrison, MD, Assistant Professor of Neuro-Oncology at MD Anderson and is now a Clinical Associate Professor BC Cancer the University of British Columbia. In this video, she speaks about the Neurologic Toxicities of Immunotherapy.   Overview:   Over the last two decades, immunotherapy has changed cancer treatment. Immunotherapy techniques’ anticancer results come at the cost of an increasing range of immune-related adverse events (irAEs) caused by cross-reactivity between tumor and normal host tissue. These negative events can occur in any organ and range in severity from moderate to severe, even life-threatening. While neurological irAEs linked with immune checkpoint inhibitors…

Daniel Rotroff, Ph.D., MSPH, senior author of the study and researcher in the Department of Quantitative Health Sciences with Cleveland Clinic’s Lerner Research Institute. Dr. Rotroff conducted the research in collaboration with Dr. Frederico Aucejo, Director of the Liver Tumor Clinic at Cleveland Clinic; and Mrs. Arshiya Mariam, lead author of the study. In this video, he speaks about Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma: a pilot study.   Overview: Origins: Current detection approaches for hepatocellular carcinoma (HCC), such as alpha fetoprotein (AFP) and ultrasound, are ineffective due to their low sensitivity. MicroRNAs (miRNAs) are short non-coding RNAs…

Daniel Rotroff, Ph.D., MSPH, senior author of the study and researcher in the Department of Quantitative Health Sciences with Cleveland Clinic’s Lerner Research Institute. Dr. Rotroff conducted the research in collaboration with Dr. Frederico Aucejo, Director of the Liver Tumor Clinic at Cleveland Clinic; and Mrs. Arshiya Mariam, lead author of the study. In this video, he speaks about Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma: a pilot study.     Overview:   Origins:   Current detection approaches for hepatocellular carcinoma (HCC), such as alpha fetoprotein (AFP) and ultrasound, are ineffective due to their low sensitivity. MicroRNAs (miRNAs) are…

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO Plenary Series 2022 – Abstract 360490: First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.   Brief Synopsis:   In adult individuals with KRAS p.G12C mutant advanced solid tumors, assess the safety and tolerability of AMG 510.   In adult participants with KRAS p.G12C mutant advanced solid tumors, calculate the maximum tolerated dosage (MTD) and/or a recommended phase 2 dose (RP2D).

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO Plenary Series 2022 – Abstract 360490: First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.   Brief Synopsis:   In adult individuals with KRAS p.G12C mutant advanced solid tumors, assess the safety and tolerability of AMG 510.   In adult participants with KRAS p.G12C mutant advanced solid tumors, calculate the maximum tolerated dosage (MTD) and/or a recommended phase 2 dose (RP2D).

Wendy Chen, MD, MPH, Assistant Professor, Medicine, Harvard Medical School, Senior Physician, Breast Oncology Center, Dana-Farber Cancer Institute. In this video, she speaks about ASCO Plenary 2022 – Abstract 360922: A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial.   Description in detail:   In early-stage node-positive HER2 negative breast cancer patients, this is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily). Hormone Receptor status (HR positive vs HR negative), body mass index (30 vs 30 kg/m2), and stage will all be…

Wendy Chen, MD, MPH, Assistant Professor, Medicine, Harvard Medical School, Senior Physician, Breast Oncology Center, Dana-Farber Cancer Institute. In this video, she speaks about ASCO Plenary 2022 – Abstract 360922: A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial.   Description in detail:   In early-stage node-positive HER2 negative breast cancer patients, this is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily). Hormone Receptor status (HR positive vs HR negative), body mass index (30 vs 30 kg/m2), and stage will all be…

Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery, and Medicine. He is the co-director of the UVA Neuro-Oncology Center at UVA Health. His specialties include clinical trials for malignant brain tumors and the management of neurological complications of cancer and its therapies. He has led or co-led numerous NCI-funded brain tumor and pharmaceutical clinical trials.   Dr. Schiff serves on the NCI brain malignancy steering committee and chairs the ECOG-ACRIN brain tumor, working group. He also serves on several editorial boards, most notably as the associate editor of the journal, Neuro-Oncology.    In this video, he speaks…

Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery, and Medicine. He is the co-director of the UVA Neuro-Oncology Center at UVA Health. His specialties include clinical trials for malignant brain tumors and the management of neurological complications of cancer and its therapies. He has led or co-led numerous NCI-funded brain tumor and pharmaceutical clinical trials.   Dr. Schiff serves on the NCI brain malignancy steering committee and chairs the ECOG-ACRIN brain tumor, working group. He also serves on several editorial boards, most notably as the associate editor of the journal, Neuro-Oncology.    In this video, he speaks…

Charles Lopez, MD, Ph.D., Associate Professor of Medicine, School of Medicine Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine Program in Molecular and Cellular Biosciences, School of Medicine at Oregon Health & Science University (OHSU). In this video, he speaks about the ASCU GI 2022 Abstract – NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).   Origins:   Patients…

Charles Lopez, MD, Ph.D., Associate Professor of Medicine, School of Medicine Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine Program in Molecular and Cellular Biosciences, School of Medicine at Oregon Health & Science University (OHSU). In this video, he speaks about the ASCU GI 2022 Abstract – NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).   Origins:   Patients…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the abstract – A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention.   Overview – Origins: Following a subclinical lymphedema (S-BCRL) intervention triggered by bioimpedance spectroscopy (BIS) or tape measurement, rates of progression to chronic breast cancer-related lymphedema (defined as a 10% arm volume change from baseline requiring complex decongestive physiotherapy [CDP]) were compared (TM). Findings and Methodologies: New breast cancer patients undergoing mastectomy/partial…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the abstract – A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention.   Overview – Origins: Following a subclinical lymphedema (S-BCRL) intervention triggered by bioimpedance spectroscopy (BIS) or tape measurement, rates of progression to chronic breast cancer-related lymphedema (defined as a 10% arm volume change from baseline requiring complex decongestive physiotherapy [CDP]) were compared (TM). Findings and Methodologies: New breast cancer patients undergoing mastectomy/partial…

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?   Overview:   Agents that target immunological checkpoints have shown promise in improving therapy outcomes in patients with lung cancer in a variety of clinical settings over the last few years. The FDA has approved PD-1/PD-L1 inhibitors alone…

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?     Overview:   Agents that target immunological checkpoints have shown promise in improving therapy outcomes in patients with lung cancer in a variety of clinical settings over the last few years. The FDA has approved PD-1/PD-L1 inhibitors…

Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis. Sierra Oncology, Inc., a late-stage biopharmaceutical company focused on developing targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study, a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and have previously received an approved JAK inhibitor. All of the trial ‘s primary and secondary…

Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis. Sierra Oncology, Inc., a late-stage biopharmaceutical company focused on developing targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study, a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and have previously received an approved JAK inhibitor. All of the trial ‘s primary and secondary…

Sepideh Gholami, MD, MAS, FACS, Liver and Pancreas Surgeon at UC Davis Medical Center, Cancer Researcher at UC Davis Health. In this video, she speaks about the ASCO GI 2022 Panel Discussion – Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.

Sepideh Gholami, MD, MAS, FACS, Liver and Pancreas Surgeon at UC Davis Medical Center, Cancer Researcher at UC Davis Health. In this video, she speaks about the ASCO GI 2022 Panel Discussion – Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.

Thomas Abrams, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GI 2022 Abstract – A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.     Origins:   Cabozantinib, a multiple receptor tyrosine kinase inhibitor, provides an immunological-permissive milieu, which may help immune checkpoint inhibitors work more effectively. The combination of cabozantinib and atezolizumab, an anti-PD-L1 agent, is being tested in COSMIC-021 (NCT03170960) in patients with advanced solid malignancies. The researchers present the results of patients with metastatic colorectal cancer…

Thomas Abrams, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GI 2022 Abstract – A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.     Origins:   Cabozantinib, a multiple receptor tyrosine kinase inhibitor, provides an immunological-permissive milieu, which may help immune checkpoint inhibitors work more effectively. The combination of cabozantinib and atezolizumab, an anti-PD-L1 agent, is being tested in COSMIC-021 (NCT03170960) in patients with advanced solid malignancies. The researchers present the results of patients with metastatic colorectal cancer…

Nazanin Majd, MD, Ph.D., BS, Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, she speaks about Immunotherapy for Neuro-oncology.    Abstract   Immunotherapy is at the forefront of cancer advances and has revolutionized the landscape of treatment for many solid and hematological malignancies. Several factors unique to the central nervous system (CNS), such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for cerebral edema management, and immunosuppressive mechanisms within the tumor and brain parenchyma, have all posed challenges in the…

Nazanin Majd, MD, Ph.D., BS, Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, she speaks about Immunotherapy for Neuro-oncology.    Abstract   Immunotherapy is at the forefront of cancer advances and has revolutionized the landscape of treatment for many solid and hematological malignancies. Several factors unique to the central nervous system (CNS), such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for cerebral edema management, and immunosuppressive mechanisms within the tumor and brain parenchyma, have all posed challenges in the…

Karyn A Goodman, MD, MS, Professor of Radiation Oncology, Professor of Medicine, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai. In this video, she speaks about SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.     Origins:   Patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC) are currently treated with definitive platinum-based concomitant chemoradiotherapy (dCRT). However, ESCC has a dismal prognosis, with more than half of tumors recurring following dCRT (Smyth et al. Nat Rev…

Karyn A Goodman, MD, MS, Professor of Radiation Oncology, Professor of Medicine, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai. In this video, she speaks about SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.     Origins:   Patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC) are currently treated with definitive platinum-based concomitant chemoradiotherapy (dCRT). However, ESCC has a dismal prognosis, with more than half of tumors recurring following dCRT (Smyth et al. Nat Rev…